Journal articles: 'Bone void filler'

1

Anonymous. "Bone Void Filler." Orthopedics 25, no. 4 (April 2002): 440. http://dx.doi.org/10.3928/0147-7447-20020401-24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dvorzhinskiy, Aleksey, Giorgio Perino, Robert Chojnowski, Marjolein C. H. van der Meulen, Mathias P. G. Bostrom, and Xu Yang. "Ceramic composite with gentamicin decreases persistent infection and increases bone formation in a rat model of debrided osteomyelitis." Journal of Bone and Joint Infection 6, no. 7 (July 20, 2021): 283–93. http://dx.doi.org/10.5194/jbji-6-283-2021.

Full text

Abstract:

Abstract. Introduction: Current methods of managing osteomyelitic voids after debridement are inadequate and result in significant morbidity to patients. Synthetic ceramic void fillers are appropriate for non-infected bone defects but serve as a nidus of re-infection in osteomyelitis after debridement. CERAMENT G (CG) is an injectable ceramic bone void filler which contains gentamicin and is currently being evaluated for use in osteomyelitic environments after debridement due to its theoretical ability to serve as a scaffold for healing while eliminating residual bacteria after debridement through the elution of antibiotics. The goal of this study was to evaluate (1) the rate of persistent infection and (2) new bone growth of a debrided osteomyelitic defect in a rat model which has been treated with either gentamicin-impregnated ceramic cement (CERAMENT G) or the same void filler without antibiotics (CERAMENT, CBVF). Methods: Osteomyelitis was generated in the proximal tibia of Sprague Dawley rats, subsequently debrided, and the defect filled with either (1) CG (n=20), (2) CBVF (n=20), or (3) nothing (n=20). Each group was euthanized after 6 weeks. Infection was detected through bacterial culture and histology. Bone growth was quantified using microCT. Results: Infection was not detected in defects treated with CG as compared with 35 % of defects (7/20) treated with CBVF and 50 % (10/20) of empty defects (p=0.001). Bone volume in the defect of CG-treated rats was greater than the CBVF (0.21 vs. 0.17, p=0.021) and empty groups (0.21 vs. 0.11, p<0.001) at 6 weeks after implantation. Conclusions: Ceramic void filler with gentamicin (CERAMENT G) decreased the rate of persistent infection and increased new bone growth as compared to the same void filler without antibiotics (CERAMENT) and an empty defect in a rat model of debrided osteomyelitis.

APA, Harvard, Vancouver, ISO, and other styles

3

Blaha, J. David. "Calcium Sulfate Bone-Void Filler." Orthopedics 21, no. 9 (September 1998): 1017–19. http://dx.doi.org/10.3928/0147-7447-19980901-31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sinha, R., PS Menon, and A. Chakranarayan. "Vitoss Synthetic Cancellous Bone (Void Filler)." Medical Journal Armed Forces India 65, no. 2 (April 2009): 173. http://dx.doi.org/10.1016/s0377-1237(09)80136-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Schendel, Stephen A., and John Peauroi. "Magnesium-Based Bone Cement and Bone Void Filler." Journal of Craniofacial Surgery 20, no. 2 (March 2009): 461–64. http://dx.doi.org/10.1097/scs.0b013e31819b9819.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Karr, Jeffrey C., Joseph Lauretta, and Georgia Keriazes. "In Vitro Antimicrobial Activity of Calcium Sulfate and Hydroxyapatite (Cerament Bone Void Filler) Discs Using Heat-Sensitive and Non–Heat-sensitive Antibiotics Against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa." Journal of the American Podiatric Medical Association 101, no. 2 (March 1, 2011): 146–52. http://dx.doi.org/10.7547/1010146.

Full text

Abstract:

Background: Several absorbable and nonabsorbable antibiotic carrier systems are available in the adjunctive surgical management of osteomyelitis of the foot, ankle, and lower leg. These carrier systems have significant limitations regarding which antibiotics can be successfully incorporated into the carrier vehicle. The calcium sulfate and hydroxyapatite Cerament Bone Void Filler is a biocompatible, absorbable ceramic bone void filler that can successfully deliver multiple heat-stable and heat-unstable antibiotics that have not been generally used before with antibiotic beads in treating musculoskeletal infections. Methods: Cerament Bone Void Filler discs with the antibiotics rifampin, vancomycin, tobramycin, cefazolin, cefepime hydrochloride, vancomycin-tobramycin, piperacillin-tazobactam, ceftazidime, and ticarcillin-clavulanate were tested in vitro against methicillin-resistant Staphylococcus aureus. Results: The zones of inhibition for the Cerament Bone Void Filler antibiotic discs plated against Staphylococcus aureus obtained were 33% to 222% greater than the minimum zones of inhibition breakpoints for bacteria susceptibility as defined by the standard set by the Clinical and Laboratory Standards Institute. Cerament Bone Void Filler discs with the antibiotics plated against Pseudomonas aeruginosa produced zones of inhibition of 93% to 200% greater than the minimum zones of inhibition breakpoints for bacteria susceptibility as defined by the standard set by the Clinical and Laboratory Standards Institute. Conclusions: The calcium sulfate and hydroxyapatite Cerament Bone Void Filler was an excellent carrier vehicle for multiple antibiotics creating in vitro significant zones of inhibition, thus demonstrating susceptibility against Staphylococcus aureus and Pseudomonas aeruginosa, which holds tremendous promise in treating osteomyeilits. (J Am Podiatr Med Assoc 101(2): 146–152, 2011)

APA, Harvard, Vancouver, ISO, and other styles

7

Pilliar, Robert M., Rita A. Kandel, Marc D. Grynpas, John Theodoropoulos, Youxin Hu, Bedilu Allo, and Adele Changoor. "Calcium polyphosphate particulates for bone void filler applications." Journal of Biomedical Materials Research Part B: Applied Biomaterials 105, no. 4 (February 1, 2016): 874–84. http://dx.doi.org/10.1002/jbm.b.33623.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Punyanitya, Sittiporn, Rungsarit Koonawoot, Warangkul Punyanitya, and Phanlob Chankachang. "A Clinical Trial for Bone Void Filler Made from Derived Hydroxyapatite from Cockle Shell Mixed with Rice Starch." Key Engineering Materials 779 (September 2018): 50–53. http://dx.doi.org/10.4028/www.scientific.net/kem.779.50.

Full text

Abstract:

In this study, we have demonstrated that bone void filler made from hydroxyapatite (HAP) which derived from cockle shell. This sample mixed with rice starch and can be used to augment new bone growth in the empty space defects of damaged hard tissue, such as bone, spine and skull. The chemical compositions of HAP get along with standard specification for composition of ceramic HAP for surgical implants (ASTM International: F1185-88). The starch content was in the safety range of classical cell culture formulation. 60 patients were treated with this bone void filler show successfully healing and recovery, after 6 months period of follow up, confirmed safety and efficacy of the medical device properties. It should be an alternative choice for bone substitute in the future.

APA, Harvard, Vancouver, ISO, and other styles

9

Karr, Jeffrey C. "An Overview of the Percutaneous Antibiotic Delivery Technique for Osteomyelitis Treatment and a Case Study of Calcaneal Osteomyelitis." Journal of the American Podiatric Medical Association 107, no. 6 (November 1, 2017): 511–15. http://dx.doi.org/10.7547/13-047.

Full text

Abstract:

Background:A percutaneous antibiotic delivery technique (PAD-T) used for the adjunctive management of osteomyelitis is presented.Methods:This surgical technique incorporates a calcium sulfate and hydroxyapatite (calcium phosphate) bone void filler acting as a carrier vehicle with either an antibiotic or an antifungal medicine, delivering this combination directly into the area of osteomyelitis.Results:The benefit of the PAD-T is reviewed with a case presentation of a successfully treated calcaneal osteomyelitis.Conclusions:No previously reported PAD-T using a simple bone cortex incision in the adjunctive treatment of osteomyelitis has been reported. The PAD-T safely and effectively uses a calcium sulfate and hydroxyapatite bone void filler carrier vehicle to deliver either an antibiotic or an antifungal medicine directly into the area of osteomyelitis.

APA, Harvard, Vancouver, ISO, and other styles

10

Axén, Niklas, Tobias Persson, Kajsa Björklund, Hakan Engqvist, and Leif Hermansson. "An Injectable Bone Void Filler Cement Based on Ca-Aluminate." Key Engineering Materials 254-256 (December 2003): 265–68. http://dx.doi.org/10.4028/www.scientific.net/kem.254-256.265.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Harris, Michael, Hamza Ahmed, Leslie Pace, Jon Minter, Michael Neel, and Jessica Jennings. "Evaluation of Antibiotic-Releasing Triphasic Bone Void Filler In-Vitro." Journal of Functional Biomaterials 9, no. 4 (September 21, 2018): 55. http://dx.doi.org/10.3390/jfb9040055.

Full text

Abstract:

Bone void fillers (BVFs) containing calcium sulfate, tricalcium phosphate (TCP), and hydroxyapatite can be loaded with antibiotics for infection treatment or prevention under surgeon-directed use. The aim of this study was to characterize the handling and elution properties of a triphasic BVF loaded with common antibiotics. BVF was mixed with vancomycin and/or tobramycin to form pellets, and the set time was recorded. A partial refreshment elution study was conducted with time points at 4, 8, and 24 h, as well as 2, 7, 14, 28, and 42 days. Effects on dissolution were evaluated in a 14-day dissolution study. Set time increased to over 1 h for groups containing tobramycin, although vancomycin had a minimal effect. Pellets continued to elute antibiotics throughout the 42-day elution study, suggesting efficacy for the treatment or prevention of orthopedic infections. BVF containing vancomycin or tobramycin showed similar dissolution at 14 days compared to BVF without antibiotics; however, BVF containing both antibiotics showed significantly more dissolution.

APA, Harvard, Vancouver, ISO, and other styles

12

Brooks, Amanda E., Benjamin D. Brooks, Sherry N. Davidoff, Paul C. Hogrebe, Mark A. Fisher, and David W. Grainger. "Polymer-controlled release of tobramycin from bone graft void filler." Drug Delivery and Translational Research 3, no. 6 (May 25, 2013): 518–30. http://dx.doi.org/10.1007/s13346-013-0155-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Karr, Jeffrey C. "Lower-Extremity Osteomyelitis Treatment Using Calcium Sulfate/Hydroxyapatite Bone Void Filler with Antibiotics." Journal of the American Podiatric Medical Association 108, no. 3 (May 1, 2018): 210–14. http://dx.doi.org/10.7547/16-096.

Full text

Abstract:

Background: Over a 74-month period (∼6 years), 143 lower-extremity osteomyelitis locations in 125 patients were treated with a calcium sulfate/hydroxyapatite liquid bone void filler with antibiotic(s). Methods: The osteomyelitis locations were treated with a percutaneous antibiotic delivery technique delivering intraosseous antibiotic followed by either oral or intravenous antibiotics for 4 weeks. Results: There was no recurrence of osteomyelitis in 96.15% of the treatable patients. Outcomes classified by the Cierny-Mader clinical classification are discussed as well. Conclusions: A bone void filler with antibiotic(s) using the percutaneous antibiotic delivery technique is a safe, reliable, and effective means to treat lower-extremity osteomyelitis with either oral or intravenous antibiotics for 4 weeks.

APA, Harvard, Vancouver, ISO, and other styles

14

Kotrych, Daniel, Szymon Korecki, Paweł Ziętek, Bartosz Kruk, Agnieszka Kruk, Michał Wechmann, Adam Kamiński, Katarzyna Kotrych, and Andrzej Bohatyrewicz. "Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions." Open Medicine 13, no. 1 (October 22, 2018): 487–92. http://dx.doi.org/10.1515/med-2018-0072.

Full text

Abstract:

AbstractBackground: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.

APA, Harvard, Vancouver, ISO, and other styles

15

Punyanitya, Sittiporn, Warangkul Punyanitya, Sakdiphon Thiansem, and Rungsarit Koonawoot. "Fabrication and Characterization of Novel Bone Void Filler Made from Hydroxyapatite-Rice Starch Composite." Key Engineering Materials 779 (September 2018): 45–49. http://dx.doi.org/10.4028/www.scientific.net/kem.779.45.

Full text

Abstract:

The aim of this study is fabricated bone void filler (BVF) made from hydroxyapatite (HA)-rice starch (RS) composite. We provided HA derived from cockle shells and RS derived from Thai rice starch. BVF was prepared by adding the pore former method to mimic the pore structure of bones. The samples were heated at 1250°C for 3 hours. Then, the composites were prepared by dipping and coating surface of the samples with RS gel. Scanning electron microscopy (SEM) and X-ray diffraction (XRD) confirmed that bovine bone and BVF are made of HA phase. Film of RS gel coated on surface of samples indicated that BVF without toxicity and would increased the proliferation of bone cells. Moreover, it was found that BVF after coated RS gel had water absorption value higher than before coated as 25% that exhibited a good capacity of regeneration bone.

APA, Harvard, Vancouver, ISO, and other styles

16

Karr, Jeffrey C. "Management in the Wound-care Center Outpatient Setting of a Diabetic Patient with Forefoot Osteomyelitis Using Cerament Bone Void Filler Impregnated with Vancomycin." Journal of the American Podiatric Medical Association 101, no. 3 (May 1, 2011): 259–64. http://dx.doi.org/10.7547/1010259.

Full text

Abstract:

Several nonbiodegradable and biodegradable antibiotic cement delivery systems are available for the delivery of antibiotics for adjunctive therapy in the management of osteomyelitis. A major nonbiodegradable delivery system is polymethylmethacrylate beads. Antibiotics that can be incorporated into this delivery system are limited to the heat-stable antibiotics vancomycin and aminoglycosides, tobramycin being the most popular. Calcium sulfate and hydroxyapatite (Cerament Bone Void Filler) is a unique biocompatible and biodegradable ceramic bone void filler that can successfully deliver heat-stable and heat-unstable antibiotics in musculoskeletal infections. The use of Cerament as antibiotic beads has not been previously reported. An off-label case of diabetic foot osteomyelitis successfully managed with surgical bone resection and vancomycin Cerament antibiotic beads is presented. Subsequent surgery for the bone infection and staged removal of the antibiotic beads was not necessary. (J Am Podiatr Med Assoc 101(3): 259–264, 2011)

APA, Harvard, Vancouver, ISO, and other styles

17

Pietrzak, William S., and Robert Ronk. "Calcium Sulfate Bone Void Filler: A Review and a Look Ahead." Journal Of Craniofacial Surgery 11, no. 4 (July 2000): 327–33. http://dx.doi.org/10.1097/00001665-200011040-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lewis, Christine S., Jordan Katz, Maribel I. Baker, Peter R. Supronowicz, Elise Gill, and Ronald R. Cobb. "Local Antibiotic Delivery with Bovine Cancellous Chips." Journal of Biomaterials Applications 26, no. 4 (September 6, 2010): 491–506. http://dx.doi.org/10.1177/0885328210375729.

Full text

Abstract:

Infected bone defects and osteomyelitis are encountered frequently in trauma cases. Currently, the standard of care for osteomyelitis cases is prolonged systemic antibiotic therapy and implantation of antibiotic carrier beads. However, this method requires a secondary surgery to remove the beads after the infection has cleared. In the present study a common bone void filler was investigated for its ability to be infused with an antibiotic. This study demonstrates that the xenograft material tested can be loaded with gentamicin and release clinically relevant levels of the drug for at least 14 days in vitro allowing for the inhibition of bacterial growth on the graft. This study also demonstrates that the levels of gentamicin released did not have an adverse effect on primary osteoblast cell proliferation or ability to generate alkaline phosphatase. This bone void filler may represent a viable alternative to current methods of local antibiotic delivery in orthopedic applications.

APA, Harvard, Vancouver, ISO, and other styles

19

Mahan, KT, and MJ Carey. "Hydroxyapatite as a bone substitute." Journal of the American Podiatric Medical Association 89, no. 8 (August 1, 1999): 392–97. http://dx.doi.org/10.7547/87507315-89-8-392.

Full text

Abstract:

A bone substitute eliminates the need for autogenous and allogeneic bone grafting, along with the complications unique to each. Coralline hydroxyapatite is a synthetic bone void filler manufactured from marine coral, which has a natural trabecular structure similar to that of cancellous bone. While initial studies have been promising, the use of coralline hydroxyapatite may be limited in the foot and ankle owing to its inherent mechanical weakness and lack of biodegradation. In this retrospective study, 20 patients who received coralline hydroxyapatite implants were reviewed to determine associated complications and host reaction to the material. The results indicate that the material is biologically inert and safe to use as a small-defect filler in low-load applications. Long-term clinical trials are needed to determine the indications for this material in the foot and ankle.

APA, Harvard, Vancouver, ISO, and other styles

20

Eriwati, Yosi Kusuma, Difa Putri Utami, Dede Arsista, Sunarso Sunarso, and Siti Triaminingsih. "Characterization of Granular Calcium Sulfate Dihydrate-Gelatin Composite for Bone Void Filler." Key Engineering Materials 829 (December 2019): 69–74. http://dx.doi.org/10.4028/www.scientific.net/kem.829.69.

Full text

Abstract:

Calcium sulfate dihydrate (CSD) cement has been used as bone filler for decades. It is also used as antibiotics carrier to treat osteomyelitis. However, CSD cement alone when applied at bone defect has some limitation such as its brittleness. The brittleness limits its handling property. Thus, the aim of this study is to fabricate granular CSD cement-gelatin (CSD-Gel) that has good handling property to be used as bone void filler. To prepare CSD-Gel composite, granular CSD was prepared from calcium sulfate hemihydrate (CaSO4.0.5H2O; CSH) and distilled water with water/powder (W/P) ratio of 0.5. The CSD cement was crushed and sieved into 300-500 μm. The obtained granular CSD was then mixed with 3 wt.% and 7 wt.% gelatin solution, followed by freeze drying for 48 hours. The CSD granules were surrounded by gelatin matrix in all specimens. It was observed that more gelatin matrix found in the space between the granules in in the composite with 7 wt% gelatin compared with that in 3 wt% gelatin. Mechanical evaluation revealed that CSD-Gel 7% has significant higher compressive strength compared with that of CSD-Gel 3%.

APA, Harvard, Vancouver, ISO, and other styles

21

Gitelis, Steven, and Gregory T. Brebach. "The Treatment of Chronic Osteomyelitis with a Biodegradable Antibiotic-Impregnated Implant." Journal of Orthopaedic Surgery 10, no. 1 (June 2002): 53–60. http://dx.doi.org/10.1177/230949900201000110.

Full text

Abstract:

The use of local antibiotics from a biodegradable implant for chronic osteomyelitis is an attractive alternative. The implant delivers high tissue levels, obliterates dead space, aids bone repair and does not need to be removed. The purpose of this paper is to review our early clinical experience with custom-made calcium sulfate (Osteoset bone void filler) antibiotic-impregnated implants.

APA, Harvard, Vancouver, ISO, and other styles

22

Jones, Tracey, and Marc Long. "Correlating In-Vitro Dissolution Measurement Methods Used with Bone Void Filler Bioceramics." Key Engineering Materials 254-256 (December 2003): 261–64. http://dx.doi.org/10.4028/www.scientific.net/kem.254-256.261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Engqvist, Hakan, S. Edlund, Gunilla Gómez-Ortega, Jesper Lööf, and Leif Hermansson. "In Vitro Mechanical Properties of a Calcium Silicate Based Bone Void Filler." Key Engineering Materials 309-311 (May 2006): 829–32. http://dx.doi.org/10.4028/www.scientific.net/kem.309-311.829.

Full text

Abstract:

The objective of the paper is to investigate the mechanical and the handling properties of a novel injectable bone void filler based on calcium silicate. The orthopaedic cement based on calcium silicate was compared to a calcium phosphate cement, Norian SRS from Syntes Stratec, with regard to the working (ejection through 14 G needle) and setting time (Gillmore needles), Young’s modulus and the flexural (ASTM F-394) and compressive (ISO 9917) strength after storage in phosphate buffer saline at body temperature for time points from 1h up to 16 weeks. The calcium silicate cement is composed of a calcium silicate powder (grain size below 20 µm) that is mixed with a liquid (water and CaCl2) into a paste using a spatula and a mixing cup. The water to cement ratio used was about 0.5. The calcium silicate had a working time of 15 minutes and a setting time of 17 minutes compared to 5 and 10 minutes respectively for the calcium phosphate cement. The compressive strength was considerably higher for the calcium silicate cement (>100 MPa) compared to the calcium phosphate cement (>40 MPa). Regarding the flexural strength the calcium silicate cement had high values for up to 1 week (> 40 MPa) but it decreased to 25 MPa after 16 weeks. The phosphate cement had a constant flexural strength of about 25 MPa. The results show that calcium silicate cement has the mechanical and handling potential to be used as high strength bone void filler.

APA, Harvard, Vancouver, ISO, and other styles

24

Hoiness, Per R. "Reply to comments on ?The use of a synthetic bone void filler...?" Archives of Orthopaedic and Trauma Surgery 124, no. 10 (September 18, 2004): 724. http://dx.doi.org/10.1007/s00402-004-0726-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lyons, Frank G., John P. Gleeson, Sonia Partap, Karen Coghlan, and Fergal J. O’Brien. "Novel Microhydroxyapatite Particles in a Collagen Scaffold: A Bioactive Bone Void Filler?" Clinical Orthopaedics and Related Research® 472, no. 4 (January 3, 2014): 1318–28. http://dx.doi.org/10.1007/s11999-013-3438-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Daculsi, G., M. Durand, T. Fabre, F. Vogt, A. P. Uzel, and J. L. Rouvillain. "Development and clinical cases of injectable bone void filler used in orthopaedic." IRBM 33, no. 4 (September 2012): 254–62. http://dx.doi.org/10.1016/j.irbm.2012.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Brooks, Benjamin D., Kristofer D. Sinclair, Sherry N. Davidoff, Scott Lawson, Alex G. Williams, Brittany Coats, David W. Grainger, and Amanda E. Brooks. "Molded polymer-coated composite bone void filler improves tobramycin controlled release kinetics." Journal of Biomedical Materials Research Part B: Applied Biomaterials 102, no. 5 (December 26, 2013): 1074–83. http://dx.doi.org/10.1002/jbm.b.33089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Jones, Zachary, Amanda E. Brooks, Zachary Ferrell, David W. Grainger, and Kristofer D. Sinclair. "A resorbable antibiotic eluting bone void filler for periprosthetic joint infection prevention." Journal of Biomedical Materials Research Part B: Applied Biomaterials 104, no. 8 (August 31, 2015): 1632–42. http://dx.doi.org/10.1002/jbm.b.33513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Gumbiner, Brandon, Elizabeth Jacobsen, Mary Stancukas, and Ngan Nguyen. "A Rare Case of Chondroblastoma with Revision After Graft Rejection." Journal of the American Podiatric Medical Association 107, no. 5 (September 1, 2017): 440–45. http://dx.doi.org/10.7547/15-216.

Full text

Abstract:

We present a rare case of calcaneal chondroblastoma with subsequent surgical revision after graft rejection in a 13-year-old boy. Complications were encountered after the injectable bone graft filler was placed in the calcaneus after curettage. With noted subsequent sinus tract formation, revision surgery was performed that involved dissection of the sinus tract, removal of bone void filler, and application of demineralized bone matrix sponge human allograft soaked in vancomycin-impregnated saline. Sixteen weeks after the revision surgical intervention, the patient resumed normal athletic activities without pain or restrictions. One and a half years after the initial surgery, the patient had complete resolution of the calcaneal cyst and was discharged.

APA, Harvard, Vancouver, ISO, and other styles

30

Shilo, Shani, Racheli Gueta, Tamar Harel-Adar, Sigal Roth, Or Dgany, Oded Shoseyov, and Hagit Amitai. "Innovative Bone Void Filler Putty Based on Recombinant Human Type-I Collagen for Spinal Bone Repair." Spine Journal 11, no. 10 (October 2011): S147. http://dx.doi.org/10.1016/j.spinee.2011.08.355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

McGee, M., C. Wildenauer, A. Kurmis, E. Margerrison, and J. R. Field. "The utilization of a synthetic bone void filler (JAX) in the repair of a femoral segmental defect." Veterinary and Comparative Orthopaedics and Traumatology 22, no. 02 (2009): 87–95. http://dx.doi.org/10.3415/vcot-08-02-0019.

Full text

Abstract:

Summary Objectives: Currently available synthetic void fillers are indicated for bony voids or gaps that are not intrinsic to the stability of the structure. Jax™ TCP (tricalcium phosphate) is an osteoconductive bioceramic fabricated into 4 mm granules with a unique interlocking form, promoting structural integrity while allowing bone in-growth. The objective of this study was to assess bone ingrowth using a large, critically sized, femoral defect. Methods: A 5 cm segmental ostectomy was created in the mid-diaphysis of 16 adult ovine femora. A stainless steel intramedullary nail was introduced and locked with two proximal and two distal fully-threaded locking screws. Each defect was surrounded with a resorbable macroporous poly (L-lactide-co-D, L) lactide mesh acting as graft containment. Treatment groups (n=4) were as follows: 1) Empty defect; 2) Morselized cortical bone; 3) Cortical strut; 4) Jax TCP. Serial radiographs were taken postoperatively and at two, four and six months. Femora retrieved at necropsy (six months) underwent computed tomography for volumetric analysis followed by histological assessment of the biological response. Results: Little bone was apparent in the empty defect group, whereas significant bone was evident in both autograft groups and the Jax TCP group. Three-dimensional CT reconstructions and volumetric analysis were in close agreement with the radiographic findings. Clinical significance: Jax TCP bone graft substitute has been proven to be effective in the healing of a large, critically sized, contained segmental defect. The healing observed was superior to that of cortical struts and the new bone laid down had similar radio-opacity to autograft.

APA, Harvard, Vancouver, ISO, and other styles

32

Laycock, Phillip, John Cooper, Robert Howlin, Craig Delury, Sean Aiken, and Paul Stoodley. "In Vitro Efficacy of Antibiotics Released from Calcium Sulfate Bone Void Filler Beads." Materials 11, no. 11 (November 13, 2018): 2265. http://dx.doi.org/10.3390/ma11112265.

Full text

Abstract:

15 different antibiotics were individually mixed with commercially available calcium sulfate bone void filler beads. The antibiotics were: amikacin, ceftriaxone, cefuroxime, ciprofloxacin, clindamycin, colistamethate sodium, daptomycin, gentamicin, imipenem/cilastatin, meropenem, nafcillin, rifampicin, teicoplanin, tobramycin and vancomycin. The efficacy of specific released antibiotics was validated by zone of inhibition (ZOI) testing using a modified Kirby–Bauer disk diffusion method against common periprosthetic joint infection pathogens. With a subset of experiments (daptomycin, rifampin, vancomycin alone and rifampin and vancomycin in combination), we investigated how release varied over 15 days using a repeated ZOI assay. We also tested the ability of these beads to kill biofilms formed by Staphylococcus epidermidis 35984, a prolific biofilm former. The results suggested that certain antibiotics could be combined and released from calcium sulfate with retained antibacterial efficacy. The daptomycin and rifampin plus vancomycin beads showed antimicrobial efficacy for the full 15 days of testing and vancomycin in combination with rifampin prevented resistant mutants. In the biofilm killing assay, all of the antibiotic combinations showed a significant reduction in biofilm bacteria after 24 h. The exposure time was an important factor in the amount of killing, and varied among the antibiotics.

APA, Harvard, Vancouver, ISO, and other styles

33

Breding, Karin, and Hakan Engqvist. "Strength and Chemical Stability Due to Aging of Two Bone Void Filler Materials." Key Engineering Materials 361-363 (November 2007): 315–18. http://dx.doi.org/10.4028/www.scientific.net/kem.361-363.315.

Full text

Abstract:

Injectable resorbable bone cements for bone void fillings are gaining in interest. The materials resorb in vivo with loss of void filling capacity and strength as a consequence. The objective with this study is to qualitative determining the dissolution behaviour for a calcium sulphate and a calcium phosphate cement as function of storage time in different storage medium and correlate to their strength development. Experiments were performed on a calcium phosphate based cement, Norian SRS, and a calcium sulphate based cement, MIIG X3. In the resorbtion study, the materials dissolution at different pH (3, 5 and 7) was compared over a period of 11 weeks. The materials compressive and biaxial flexural strength was measured after aging in phosphate buffer saline for up to 12 weeks. The proposed qualitative method to study dissolution behaviour of injectable biomaterials as function of time and medium were evaluated and proved to be useful. Both materials were dissolved after 3 weeks of storage in pH 3. MIIG X3 dissolved faster than Norian SRS at pH 5. At pH 7 both materials were stable over the test period of 11 weeks. For both materials the strength decreases with storage time. Norian had a higher compressive strength than MIIG X3 for the first week, after the first week the compressive strength was similar for the two materials. MIIG X3 showed a higher flexural strength than Norian during the full test period.

APA, Harvard, Vancouver, ISO, and other styles

34

Pomrink, G. J., M. P. DiCicco, T. D. Clineff, and E. M. Erbe. "Evaluation of the reaction kinetics of CORTOSSTM, a thermoset cortical bone void filler." Biomaterials 24, no. 6 (March 2003): 1023–31. http://dx.doi.org/10.1016/s0142-9612(02)00443-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Shiels, S. M., R. R. Cobb, K. M. Bedigrew, G. Ritter, J. F. Kirk, A. Kimbler, I. Finger Baker, and J. C. Wenke. "Antibiotic-loaded bone void filler accelerates healing in a femoral condylar rat model." Bone & Joint Journal 98-B, no. 8 (August 2016): 1126–31. http://dx.doi.org/10.1302/0301-620x.98b8.37634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Voleti, Pramod B., Christopher L. Camp, Alec L. Sinatro, and Joshua S. Dines. "Arthroscopic Removal of Symptomatic Proximal Humerus Locking Plates With Bone-Void Filler Augmentation." Arthroscopy Techniques 5, no. 2 (April 2016): e343-e346. http://dx.doi.org/10.1016/j.eats.2016.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Glaeser, Juliane D., Khosrowdad Salehi, Linda EA Kanim, Derek G. Ju, Jae Hyuk Yang, Phillip H. Behrens, Samuel A. Eberlein, et al. "Electrospun, synthetic bone void filler promotes human MSC function and BMP-2 mediated spinal fusion." Journal of Biomaterials Applications 35, no. 4-5 (July 5, 2020): 532–43. http://dx.doi.org/10.1177/0885328220937999.

Full text

Abstract:

Introduction Synthetic bone grafts are often used to achieve a well-consolidated fusion mass in spinal fusion procedures. These bone grafts function as scaffolds, and ideally support cell function and facilitate protein binding. Objective The aim was to characterize an electrospun, synthetic bone void filler (Reb) for its bone morphogenetic protein (BMP)-2 release properties and support of human mesenchymal stem cell (hMSC) function in vitro, and its efficacy in promoting BMP-2-/bone marrow aspirate-(BMA)-mediated posterolateral spinal fusion (PLF) in vivo. Methods BMP-2 release kinetics from Reb versus standard absorbable collagen sponge (ACS) was determined. hMSC adhesion and proliferation on Reb was tested using cell counting, fluorescence microscopy and MTS. Cell osteogenic differentiation was quantified via cellular alkaline phosphatase (ALP) activity. For in vivo analysis, 18 Lewis rats were treated during PLF surgery with the following groups: (I) Reb + BMA, (II) Reb + BMA + BMP-2 and (III) BMA. A safe, minimally effective dose of BMP-2 was used. Fusion consolidation was followed for 3 months using radiography and micro-CT. After sacrifice, fusion rate and biomechanical stiffness was determined using manual palpation, biomechanical tests and histology. Results In vitro, BMP-2 release kinetics were similar between Reb versus ACS. MSC proliferation and differentiation were increased in the presence of Reb. At 3 months post-surgery, fusion rates were 29% (group I), 100% (group II), and 0% (group III). Biomechanical stiffness was higher in group II versus I. Micro-CT showed an increased bone volume and connectivity density in group II. Trabecular thickness was increased in group I versus II. H&E staining showed newly formed bone in group II only. Conclusions Reb possesses a high protein binding affinity and promotes hMSC function. Combination with BMA and minimal dose BMP-2 allowed for 100% bone fusion in vivo. This data suggests that a minimally effective dose of BMP-2 can be used when combined with Reb.

APA, Harvard, Vancouver, ISO, and other styles

38

Daculsi, G., Marlene Durand, O. Hauger, Seris Elodie, Pascal Borget, Racquel Z. LeGeros, and J. C. Le Huec. "Self Hardening Macroporous Biphasic Calcium Phosphate Bone Void Filler for Bone Reconstruction; Animal Study and Human Data." Key Engineering Materials 493-494 (October 2011): 709–13. http://dx.doi.org/10.4028/www.scientific.net/kem.493-494.709.

Full text

Abstract:

Due to the lack of macroporosity in current available Calcium Phosphate cement used in osteoarticular surgery, Micro and Macroporous Biphasic CaP Cement (MCPC™) was developed. The MCPC™ concept was the association of a settable and a fast resorbable matrix and a sieved fraction of microporous biphasic calcium phosphate (BCP) granules, recognized for the high osteoconductive and osteogenic properties. During the resorption of the matrix, a porous structure is created and the osteoconductive effect of the granules promotes the bone ingrowth. A goat preclinical study was realized to evaluate the efficacy of MCPC™ for C3 and C4 vertebral body filling defects during 6 months. Bone remodelling was evidenced demonstrating bone ingrowth at the expense of the cement and surrounding the residual BCP granules. Bone trabeculae were observed coming from the spongious bone to the implant site. Human vertebral body filling cases demonstrated the biocompatibility and the safety of MCPC™ for bone reconstruction. Results of this study demonstrated the importance of special combination of calcium phosphate granules in the MCPC™ to provide macroporosity and scaffolding for newly formed bone.

APA, Harvard, Vancouver, ISO, and other styles

39

McGee, M., R. Stanley, G. Ruthenbeck, T. Papadimitrakis, A. Zannettino, S. Gronthos, S. Itescu, and J. R. Field. "The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect." Veterinary and Comparative Orthopaedics and Traumatology 24, no. 02 (2011): 113–21. http://dx.doi.org/10.3415/vcot-10-03-0046.

Full text

Abstract:

Summary Introduction: Synthetic void-fillers offer an alternative to autograft or allograft bone in the repair of segmental defects. However, the reparative process is delayed as only osteo-conductive elements are present. The inclusion of pluripotential cells may resolve this limitation, and the use of allogeneic tissue provides the opportunity for an off-the-shelf remedy. The current study evaluated the utilisation of mesenchymal precursor cells (MPC) for the repair of an ovine critical-size tibial segmental defect. Methods: Twenty-four, mature female sheep underwent surgery for the creation of a 3 cm tibial diaphyseal defect. In one group of 12 sheep the scaffold was used alone, and in the second group the scaffold was seeded with MPC. The defect was stabilised using a locking intramedullary nail and allowed to heal over a nine-month-period. Outcome assessments of healing included radiology of callus formation, computed tomography, assessment of new-bone volume, mechanical attributes, and histological evaluation of linear bone apposition rate and tissue response. Results: The MPC-treated group displayed a significantly greater level of callus formation and rate of bone apposition in the defect. Discussion: The incorporation of allogeneic MPC to a synthetic void filler stimulated early repair of critical-size diaphyseal segmental defects and holds potential as an off-the-shelf therapy for augmenting bone regeneration.

APA, Harvard, Vancouver, ISO, and other styles

40

Dumas, Jerald E., Katarzyna Zienkiewicz, Shaun A. Tanner, Edna M. Prieto, Subha Bhattacharyya, and Scott A. Guelcher. "Synthesis and Characterization of an Injectable Allograft Bone/Polymer Composite Bone Void Filler with Tunable Mechanical Properties." Tissue Engineering Part A 16, no. 8 (August 2010): 2505–18. http://dx.doi.org/10.1089/ten.tea.2009.0672.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

E., Erbe, Marx J., Clineff T., and Bellincampi L. "Potential of an ultraporous ?-tricalcium phosphate synthetic cancellous bone void filler and bone marrow aspirate composite graft." European Spine Journal 10 (October 1, 2001): S141—S146. http://dx.doi.org/10.1007/s005860100287.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Karr, Jeffrey C. "Calcium Sulfate/Calcium Phosphate Bone Void Filler in the Treatment of Bilateral Adolescent Unicameral Calcaneal Bone Cysts: 36-Month Follow-Up." Journal of the American Podiatric Medical Association 109, no. 5 (September 1, 2019): 379–88. http://dx.doi.org/10.7547/17-020.

Full text

Abstract:

A 36-month follow-up of the management of bilateral adolescent unicameral bone cysts in a high school gymnast treated with a calcium sulfate/calcium phosphate (CSCP) bone void filler (BVF) is presented. The more developed left calcaneal cyst was managed with a traditional, open approach consisting of allogenic bone graft, CSCP BVF mixed with platelet-rich plasma. The less developed right calcaneal cyst was managed with a less used approach, a percutaneous bone cortex incision with only the CSCP BVF. The rationale for the selection between the open and percutaneous approaches, long-term BVF incorporation, and positive patient outcome allowing a quick return to athletics are presented.

APA, Harvard, Vancouver, ISO, and other styles

43

Ferrell, Z., DW Grainger, and KD Sinclair. "Antibiotic-eluting resorbable bone-void filler evaluated in a large animal infection prevention model." European Cells and Materials 37 (April 8, 2019): 265–76. http://dx.doi.org/10.22203/ecm.v037a16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Brooks, Benjamin D. "Comparisons of Release of Several Antibiotics from Antimicrobial Polymer-Coated Allograft Bone Void Filler." International Journal of Biomedical Materials Research 1, no. 2 (2013): 21. http://dx.doi.org/10.11648/j.ijbmr.20130102.11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Branch, Eric A., Ashley H. Ali, and Christopher E. Baker. "Novel Use of Calcium Phosphate Bone Void Filler in Rotator Cuff and Labral Repair." Techniques in Shoulder & Elbow Surgery 20, no. 1 (March 2019): 19–25. http://dx.doi.org/10.1097/bte.0000000000000163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Diaz, Miguel A., Eric A. Branch, Luis A. Paredes, Emily Oakley, and Christopher E. Baker. "Calcium Phosphate Bone Void Filler Increases Threaded Suture Anchor Pullout Strength: A Biomechanical Study." Arthroscopy: The Journal of Arthroscopic & Related Surgery 36, no. 4 (April 2020): 1000–1008. http://dx.doi.org/10.1016/j.arthro.2019.12.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Jónsson, B. Y., and B. Mjöberg. "Porous titanium granules are better than autograft bone as a bone void filler in lateral tibial plateau fractures." Bone & Joint Journal 97-B, no. 6 (June 2015): 836–41. http://dx.doi.org/10.1302/0301-620x.97b6.34552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Karr, Jeffrey C., and Joseph Lauretta. "In Vitro Activity of Calcium Sulfate and Hydroxyapatite Antifungal Disks Loaded with Amphotericin B or Voriconazole in Consideration for Adjunctive Osteomyelitis Management." Journal of the American Podiatric Medical Association 105, no. 2 (March 1, 2015): 104–10. http://dx.doi.org/10.7547/0003-0538-105.2.104.

Full text

Abstract:

Background Regarding antibiotic-loaded cements, there is an abundant amount of literature regarding the antibacterial in vitro inhibitory and clinical applications for the treatment of osteomyelitis. The opposite can be said about literature regarding in vitro antifungal-loaded cement drug delivery for the treatment of fungal osteomyelitis. Methods Aspergillus fumigatus and Candida (ATCC 1023ATCC, Manassas, Virginia) were plated on antibiotic/antifungal-free plates. Voriconazole- and amphotericin B–impregnated calcium sulfate and hydroxyapatite (HA) disks, calcium sulfate + HA control disks, and control polymethylmethacrylate disks were laid separately onto plates separately inoculated with Aspergillus and Candida spp. The zones of inhibition obtained were measured in millimeters at 24, 36, and 96 hours. Results Etest (bioMérieux, Marcy l'Etoile, France) results demonstrated susceptibility of Aspergillus and Candida to amphotericin B and voriconazole. The zone of inhibition data demonstrated that voriconazole and amphotericin B retained their antifungal activity when mixed into the calcium sulfate + HA bone void filler and eluted at biologically effective antifungal concentrations over 96 hours. Conclusions The calcium sulfate + HA bone void filler is a biocompatible ceramic carrier vehicle that can successfully deliver the antifungal drugs voriconazole and amphotericin B in the adjunctive treatment of fungal osteomyelitis. It is a reliable strategy in the local delivery of antifungal drugs to an area of osteomyelitis.

APA, Harvard, Vancouver, ISO, and other styles

49

Pietrzak, William S., and Barry L. Eppley. "In Vitro Analysis of the Elution of Tobramycin From a Calcium Sulfate Bone Void Filler." Journal of Craniofacial Surgery 15, no. 5 (September 2004): 752–57. http://dx.doi.org/10.1097/00001665-200409000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Tse, Brian K., Zackary D. Vaughn, Derek P. Lindsey, and Jason L. Dragoo. "Evaluation of a one-stage ACL revision Technique using bone void filler after cyclic loading." Knee 19, no. 4 (August 2012): 477–81. http://dx.doi.org/10.1016/j.knee.2011.06.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Bone void filler'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles